Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis

Published:2021-01 Issue: Volume:163 Page:105256
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Li Jing,Xie Qiong-Hong,You Li,Xu Ning-Xin,Hao Chuan-Ming

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Pharmacology

Reference55 articles.

1. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017;GBD Chronic Kidney Disease Collaboration;Lancet.,2020

2. KDOQI clinical practice guidelines and clinical practice recommendations for Anemia in chronic kidney disease;National Kidney Foundation;Am. J. Kidney Dis.,2006

3. Health-related quality of life and hemoglobin levels in chronic kidney disease patients;Finkelstein;Clin. J. Am. Soc. Nephrol.,2009

4. Update on Anemia in ESRD and earlier stages of CKD: core curriculum;Fishbane;Am. J. Kidney Dis.,2018

5. Anemia of chronic disease;Weiss;N. Engl. J. Med.,2005

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for treatment of anemia in chronic kidney disease: a systematic review and network meta-analysis;Frontiers in Pharmacology;2024-07-10

2. The Efficacy and Safety of Roxadustat for the Treatment of Posttransplantation Anemia: A Randomized Study;Kidney International Reports;2024-06

3. Impact of C-reactive protein on the effect of Roxadustat for the treatment of anemia in chronic kidney disease: a systematic review of randomized controlled trials;BMC Nephrology;2024-02-05

4. HIF-PHD inhibitor desidustat ameliorates iron deficiency anemia;Toxicology and Applied Pharmacology;2024-02

5. Efficacy and safety of hypoxia-inducible factor-prolyl hydroxylase inhibitor treatment for anemia in chronic kidney disease: an umbrella review of meta-analyses;Frontiers in Pharmacology;2023-11-30